PMID- 38375839
OWN - NLM
STAT- Publisher
LR  - 20240220
IS  - 1875-5666 (Electronic)
IS  - 1566-5240 (Linking)
DP  - 2024 Feb 19
TI  - A Systematic Review of the Impact of Resveratrol on Viral Hepatitis and Chronic 
      Viral Hepatitis-related Hepatocellular Carcinoma.
LID - 10.2174/0115665240284347240125072555 [doi]
AB  - BACKGROUND: Resveratrol (RSV) is used for the treatment of various diseases due 
      to their anti-inflammatory and antioxidant activities. However, its beneficial 
      aspects on viral hepatitis have been less investigated. OBJECTIVE: This report 
      reviews the impact of resveratrol on viral hepatitis and chronic viral 
      hepatitis-related hepatocellular carcinoma (HCC). METHODS: The systematic review 
      was performed and reported according to the PRISMA 2020 statement. Several core 
      databases, such as Cochrane Library, PubMed, Web of Science, EMBASE, and Scopus, 
      were used for search on September 6, 2023. After extraction of the data, the 
      desired information of the full text of the studies was recorded in Excel, and 
      the outcomes and mechanisms were reviewed. RESULTS: RSV inhibits viral 
      replication through anti-HCV NS3 helicase activity, maintains redox homeostasis 
      via glutathione (GSH) synthesis, improves T and B cell activity, and suppresses 
      miR-155 expression. It also enhances viral replication by enhancing hepatitis C 
      virus (HCV) RNA transcription, activating sirtuin-1 (SIRT1), which can increase 
      peroxisome proliferator-activated receptor (PPAR), and SIRT1 activates the HBV X 
      protein (HBx). Moreover, RSV is responsible for hepatitis-related HCC 
      proliferation via suppression of mammalian target of rapamycin (mTOR), SIRT1 
      up-regulation, inhibiting expression of HBx, and reducing expression of cyclin 
      D1. CONCLUSION: Despite the promising properties of RSV in inhibiting 
      hepatitis-related HCC cell proliferation, its antiviral effects in viral 
      hepatitis are controversial. The antihepatitis behaviors of RSV are mainly 
      dose-dependent, and in some studies, activating some hepatoprotective pathways 
      increases the transcription and replication of chronic HBV and HCV. Therefore, 
      healthcare providers should be aware of viral hepatitis before using RSV 
      supplements.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Darvishi, Mohammad
AU  - Darvishi M
AUID- ORCID: 0000-0003-0332-2489
AD  - Infectious Diseases and Tropical Medicine Research Center (IDTMRC), School of 
      Aerospace and Subaquatic Medicine, Aja University of Medical Sciences, Tehran, 
      Iran.
FAU - Nouri, Majid
AU  - Nouri M
AUID- ORCID: 0000-0002-4110-7141
AD  - Infectious Diseases and Tropical Medicine Research Center (IDTMRC), Aja 
      University of Medical Sciences, Tehran, Iran.
FAU - Rahimi, Rasoul
AU  - Rahimi R
AUID- ORCID: 0000-0002-2176-6035
AD  - Department of Surgery, Shahrekord University of Medical Sciences, Shahrekord, 
      Iran.
FAU - Heidari-Soureshjani, Saeid
AU  - Heidari-Soureshjani S
AUID- ORCID: 0000-0002-7592-3868
AD  - Modeling in Health Research Center, Shahrekord University of Medical Sciences, 
      Shahrekord, Iran.
FAU - Hashemi Rafsanjani, Seyed Mahmood Reza
AU  - Hashemi Rafsanjani SMR
AUID- ORCID: 0009-0003-2379-9628
AD  - Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, 
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20240219
PL  - Netherlands
TA  - Curr Mol Med
JT  - Current molecular medicine
JID - 101093076
SB  - IM
OTO - NOTNLM
OT  - Resveratrol
OT  - hepatitis
OT  - hepatocellular carcinoma
OT  - side effect
OT  - viral replication
EDAT- 2024/02/20 12:51
MHDA- 2024/02/20 12:51
CRDT- 2024/02/20 07:54
PHST- 2023/10/12 00:00 [received]
PHST- 2023/12/14 00:00 [revised]
PHST- 2023/12/18 00:00 [accepted]
PHST- 2024/02/20 12:51 [medline]
PHST- 2024/02/20 12:51 [pubmed]
PHST- 2024/02/20 07:54 [entrez]
AID - CMM-EPUB-138603 [pii]
AID - 10.2174/0115665240284347240125072555 [doi]
PST - aheadofprint
SO  - Curr Mol Med. 2024 Feb 19. doi: 10.2174/0115665240284347240125072555.